Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in

Uni-Bio Science Group Limited Announces 2024 Interim Results
Uni-Bio Science Group Limited Announces 2024 Interim Results
Uni-Bio Science Group Limited Announces 2024 Interim Results
EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through

Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcarehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare


Pfizer Inc. (NYSE: PFE) today introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the

Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccinehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine


Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License

Siegfried continues to grow and increases profitability
Siegfried continues to grow and increases profitability
Siegfried continues to grow and increases profitability
Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png
Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of

Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference:
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference


Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024.



Bernard Zovighian, chief executive officer

EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
Premier, Inc. Reports Fiscal-Year 2024 Fourth-Quarter and Full-Year Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2024 Fourth-Quarter and Full-Year Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 fourth quarter and full year ended June 30, 2024

Premier, Inc. Appoints Glenn Coleman as Chief Administrative and Financial Officer: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Appoints Glenn Coleman as Chief Administrative and Financial Officer


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that Glenn Coleman, CPA, was unanimously appointed by the Board of Directors to serve as

Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on August 15, 2024, a

AllSpire Health Partners Selects Premier, Inc. as its National GPO: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
AllSpire Health Partners Selects Premier, Inc. as its National GPO


Premier, Inc. (NASDAQ: PINC), a leading technology-enabled healthcare improvement company, today announced that it has been selected by AllSpire Health GPO, LLC (AllSpire), a regional group

LivaNova to Present at the Baird Global Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present at the Baird Global Healthcare Conference


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global

Inaugural Humana Community Day Promotes Health Benefits of Volunteerism: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Inaugural Humana Community Day Promotes Health Benefits of Volunteerism


Several thousand green-shirted Humana employees will volunteer in Louisville on Aug. 21, marking the anniversary of the company’s founding, demonstrating Humana’s commitment to its hometown and

QuidelOrtho to Participate in Upcoming Investor Conferences: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Participate in Upcoming Investor Conferences


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

Savara Announces New Employment Inducement Grant: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.



On August 15, 2024

Humana Announces New Veteran Hiring Strategy and Recognition as Top Veteran-Friendly Company: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Announces New Veteran Hiring Strategy and Recognition as Top Veteran-Friendly Company


Humana Inc. (NYSE: HUM), a leading health and well-being company, launches a refreshed military-connected hiring strategy and earns recognition by U.S. Veterans Magazine as a Top Veteran-Friendly

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age


Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine

Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance:
Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance


Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024


Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through